There are 2789 resources available
234P - Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3)
Presenter: Hope Rugo
Session: ePoster Display
236P - Real-world comparative effectiveness of palbociclib plus letrozole vs letrozole in older patients with metastatic breast cancer
Presenter: Hope Rugo
Session: ePoster Display
Resources:
Abstract
Slides
237P - Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune checkpoint inhibitors (ICI)
Presenter: Saranya Chumsri
Session: ePoster Display
238P - BOLERO-5: A phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER+/HER2- advanced breast cancer
Presenter: Zhimin Shao
Session: ePoster Display
239P - Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
Presenter: Marzia Del Re
Session: ePoster Display
240P - A real-world data analysis: The first United Kingdom experience of cyclin-dependent kinase 4/6 inhibitor in advanced breast cancer in the National Health Service within an access program
Presenter: Carlo Palmieri
Session: ePoster Display
241P - Abemaciclib plus fulvestrant in participants with HR+/HER2- advanced breast cancer: A pooled analysis of the endocrine therapy naïve (EN) participants in MONARCH 2
Presenter: Jose Luis-Gonzalez Trujillo
Session: ePoster Display
242P - Impact of metastases directed radiation therapy on CDK4/6 inhibitors treatment for metastatic breast cancer
Presenter: Icro Meattini
Session: ePoster Display